A case report of cStage IIIB squamous cell lung carcinoma completely resected after downstaging with neoadjuvant therapy

Scientific paper - Case study

• Author: Jijia Li
• Author: Peng Zu
• Author: Marko Jakopović
• Author: Antoine Legras
• Author: Hisashi Saji
• Author: Ken Onodera
• Author: Georg Schlachtenberger
• Author: Hongxu Liu
• Author's institution: University of Zagreb; School of Medicine; (Department of Internal Medicine)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Internal Medicine

Abstract (english)

Background: The most effective method and length of time for administering adjuvant immunotherapy after surgery for non-small cell lung cancer (NSCLC) are still unknown. Various clinical trials have utilized diverse strategies for adjuvant treatment. In this case, we explore the potential benefits of neoadjuvant immunotherapy combined with chemotherapy in managing locally advanced lung squamous carcinoma, which often poses challenges for treatment. This multimodal approach aims to downstage tumors and optimize surgical outcomes.

Case description: Following a diagnosis of stage IIIB lung cancer, the patient underwent three cycles of neoadjuvant therapy using sintilimab, Abraxane, and Lobaplatin, resulting in a significant 45% reduction in tumor size. Subsequently, a right lower lobe lobectomy and systematic lymphadenectomy were performed using a uniportal video-assisted thoracic surgery (VATS) approach. Postoperative analysis revealed negative lymph nodes, with only a 5-mm residual tumor in the tumor bed, downstaging the cancer to IA1. Remarkably, the patient experienced a smooth recovery without any postoperative complications. One cycle of adjuvant therapy was administered following the operation to further support the patient's recovery and minimize the risk of disease recurrence. This comprehensive treatment approach underscores the importance of neoadjuvant therapy in optimizing surgical outcomes and improving long-term prognosis for patients with locally advanced lung cancer.

Conclusions: For patients with stage III locally advanced lung squamous carcinoma, the combination of Sintilimab and Platinum-based drugs can be used as a neoadjuvant therapy which can reduce the difficulty of the operation.

• Keywords (english): Case report; neoadjuvant therapy; sintilimab; squamous cell lung carcinoma
• Language: english
• Publication type: Scientific paper - Case study
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Journal of Thoracic Disease
• Numbering: vol. 16, no. 5, pp. 3503-3511
• p-ISSN: 2072-1439
• e-ISSN: 2077-6624
• DOI: https://doi.org/10.21037/jtd-24-522
• URN:NBN: urn:nbn:hr:105:320848
• Publication: 2024-05-21
• Document URL: https://jtd.amegroups.com/article/view/86692/html
• Type of resource: Text
• Access conditions: Open access
• Created on: 2025-01-27 09:11:06